| Literature DB >> 31200351 |
Martin S Tallman1, Eunice S Wang2, Jessica K Altman3, Frederick R Appelbaum4, Vijaya Raj Bhatt5, Dale Bixby6, Steven E Coutre7, Marcos De Lima8, Amir T Fathi9, Melanie Fiorella10, James M Foran11, Aric C Hall12, Meagan Jacoby13, Jeffrey Lancet14, Thomas W LeBlanc15, Gabriel Mannis7, Guido Marcucci16, Michael G Martin17, Alice Mims18, Margaret R O'Donnell16, Rebecca Olin19, Deniz Peker20, Alexander Perl21, Daniel A Pollyea22, Keith Pratz23, Thomas Prebet24, Farhad Ravandi25, Paul J Shami26, Richard M Stone27, Stephen A Strickland28, Matthew Wieduwilt10, Kristina M Gregory, Lydia Hammond29, Ndiya Ogba29.
Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. Recent advances have resulted in an expansion of treatment options for AML, especially concerning targeted therapies and low-intensity regimens. This portion of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for AML focuses on the management of AML and provides recommendations on the workup, diagnostic evaluation and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31200351 DOI： 10.6004/jnccn.2019.0028
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908